CN101824036A - 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 - Google Patents

四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN101824036A
CN101824036A CN200910047075A CN200910047075A CN101824036A CN 101824036 A CN101824036 A CN 101824036A CN 200910047075 A CN200910047075 A CN 200910047075A CN 200910047075 A CN200910047075 A CN 200910047075A CN 101824036 A CN101824036 A CN 101824036A
Authority
CN
China
Prior art keywords
acid
salt
pyrazine
trifluorophenyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200910047075A
Other languages
English (en)
Chinese (zh)
Inventor
邓炳初
孙飘扬
杨方龙
梁金栋
沈光远
王阳
范江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Priority to CN200910047075A priority Critical patent/CN101824036A/zh
Priority to AU2010220722A priority patent/AU2010220722B2/en
Priority to JP2011552307A priority patent/JP5976322B2/ja
Priority to PCT/CN2010/000257 priority patent/WO2010099698A1/zh
Priority to MX2011009190A priority patent/MX2011009190A/es
Priority to KR1020117020764A priority patent/KR101731602B1/ko
Priority to RU2011137858/04A priority patent/RU2523543C2/ru
Priority to HK11108763.5A priority patent/HK1154574B/xx
Priority to CA2753862A priority patent/CA2753862C/en
Priority to CN2010800026815A priority patent/CN102159578B/zh
Priority to UAA201110708A priority patent/UA106225C2/ru
Priority to EP10748288.7A priority patent/EP2404921B1/en
Publication of CN101824036A publication Critical patent/CN101824036A/zh
Priority to US13/225,050 priority patent/US8518946B2/en
Priority to ZA2011/07284A priority patent/ZA201107284B/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200910047075A 2009-03-05 2009-03-05 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 Pending CN101824036A (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN200910047075A CN101824036A (zh) 2009-03-05 2009-03-05 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
HK11108763.5A HK1154574B (en) 2009-03-05 2010-03-03 Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof
CA2753862A CA2753862C (en) 2009-03-05 2010-03-03 Tetrahydro-imidazo[1,5-.alpha.]pyrazine derivatives salts, preparation methods and medicinal use thereof
PCT/CN2010/000257 WO2010099698A1 (zh) 2009-03-05 2010-03-03 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
MX2011009190A MX2011009190A (es) 2009-03-05 2010-03-03 Sales derivadas de tetrahidro-imidazo[1,5-a]piracina, metodos de preparacion y uso medicinal de las mismas.
KR1020117020764A KR101731602B1 (ko) 2009-03-05 2010-03-03 테트라하이드로―이미다조[1,5―a]피라진 유도체 염, 이의 제조방법 및 용도
RU2011137858/04A RU2523543C2 (ru) 2009-03-05 2010-03-03 Соли производных тетерагидро-имидазо[1,5-a]пиразина, способы их получения и их медицинское применение
AU2010220722A AU2010220722B2 (en) 2009-03-05 2010-03-03 Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof
JP2011552307A JP5976322B2 (ja) 2009-03-05 2010-03-03 テトラヒドロ−イミダゾ[1,5−a]ピラジン誘導体塩、その製造方法及び医薬用途
CN2010800026815A CN102159578B (zh) 2009-03-05 2010-03-03 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
UAA201110708A UA106225C2 (ru) 2009-03-05 2010-03-03 СОЛИ ПРОИЗВОДНЫХ ТЕТРАГИДРОИМИДАЗО[1,5-а]ПИРАЗИНА, СПОСОБ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
EP10748288.7A EP2404921B1 (en) 2009-03-05 2010-03-03 SALTS OF TETRAHYDROIMIDAZO[1,5-a]PYRAZINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USE THEREOF
US13/225,050 US8518946B2 (en) 2009-03-05 2011-09-02 Salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-trifluoromethyl-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine-1-carboxylic acid, preparation method and medical use thereof
ZA2011/07284A ZA201107284B (en) 2009-03-05 2011-10-05 Tetrahydro-imidazo[1,5-a]pyrazine derivatives salts, preparation methods and medicinal use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200910047075A CN101824036A (zh) 2009-03-05 2009-03-05 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CN101824036A true CN101824036A (zh) 2010-09-08

Family

ID=42688223

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200910047075A Pending CN101824036A (zh) 2009-03-05 2009-03-05 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
CN2010800026815A Active CN102159578B (zh) 2009-03-05 2010-03-03 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800026815A Active CN102159578B (zh) 2009-03-05 2010-03-03 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用

Country Status (12)

Country Link
US (1) US8518946B2 (cg-RX-API-DMAC7.html)
EP (1) EP2404921B1 (cg-RX-API-DMAC7.html)
JP (1) JP5976322B2 (cg-RX-API-DMAC7.html)
KR (1) KR101731602B1 (cg-RX-API-DMAC7.html)
CN (2) CN101824036A (cg-RX-API-DMAC7.html)
AU (1) AU2010220722B2 (cg-RX-API-DMAC7.html)
CA (1) CA2753862C (cg-RX-API-DMAC7.html)
MX (1) MX2011009190A (cg-RX-API-DMAC7.html)
RU (1) RU2523543C2 (cg-RX-API-DMAC7.html)
UA (1) UA106225C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010099698A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107284B (cg-RX-API-DMAC7.html)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724352A (zh) * 2012-10-16 2014-04-16 上海源力生物技术有限公司 一种dpp-iv抑制剂的中间体、其制备方法和通过其制备dpp-iv抑制剂的方法
CN103833760A (zh) * 2013-12-20 2014-06-04 南京华威医药科技开发有限公司 哌嗪类衍生物
CN103910734A (zh) * 2014-03-28 2014-07-09 南京华威医药科技开发有限公司 一种具有哌嗪结构的dpp-4抑制剂
CN113474346A (zh) * 2018-12-28 2021-10-01 福马治疗有限公司 用于抑制泛素特异性蛋白酶1的组合物
CN113620957A (zh) * 2020-05-08 2021-11-09 盛世泰科生物医药技术(苏州)有限公司 一种胺甲基吡嗪类化合物的制备方法
CN113773323A (zh) * 2020-06-10 2021-12-10 江苏恒瑞医药股份有限公司 3r-氨基取代丁酰胺衍生物的制备方法
CN113880825A (zh) * 2020-07-01 2022-01-04 浙江海正药业股份有限公司 四氢异喹啉类衍生物的盐、其制备方法及其医药应用
CN114057751A (zh) * 2022-01-17 2022-02-18 盛世泰科生物医药技术(苏州)有限公司 一种dpp-iv抑制剂及其关键中间体的制备方法
CN115583935A (zh) * 2022-11-03 2023-01-10 浙江工业大学 一种4-(2,4,5-三氟苯基)-3-氧丁酸酯的制备方法
US12043623B2 (en) 2015-11-20 2024-07-23 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899048B (zh) * 2009-05-27 2013-04-17 上海恒瑞医药有限公司 (R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
CN119613408A (zh) 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
MX2020003451A (es) 2017-10-31 2020-08-03 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.
JP2024504328A (ja) * 2021-01-21 2024-01-31 ザ スクリプス リサーチ インスティテュート 肺疾患の治療のための肺胞2型細胞増殖の小分子調節因子

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724352B (zh) * 2012-10-16 2017-11-28 江苏盛迪医药有限公司 一种dpp‑iv抑制剂的中间体、其制备方法和通过其制备dpp‑iv抑制剂的方法
CN103724352A (zh) * 2012-10-16 2014-04-16 上海源力生物技术有限公司 一种dpp-iv抑制剂的中间体、其制备方法和通过其制备dpp-iv抑制剂的方法
CN103833760A (zh) * 2013-12-20 2014-06-04 南京华威医药科技开发有限公司 哌嗪类衍生物
CN103833760B (zh) * 2013-12-20 2016-01-20 南京华威医药科技开发有限公司 哌嗪类衍生物
CN103910734A (zh) * 2014-03-28 2014-07-09 南京华威医药科技开发有限公司 一种具有哌嗪结构的dpp-4抑制剂
CN103910734B (zh) * 2014-03-28 2016-01-13 南京华威医药科技开发有限公司 一种具有哌嗪结构的dpp-4抑制剂
US12043623B2 (en) 2015-11-20 2024-07-23 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
CN113474346A (zh) * 2018-12-28 2021-10-01 福马治疗有限公司 用于抑制泛素特异性蛋白酶1的组合物
CN113620957A (zh) * 2020-05-08 2021-11-09 盛世泰科生物医药技术(苏州)有限公司 一种胺甲基吡嗪类化合物的制备方法
CN113773323A (zh) * 2020-06-10 2021-12-10 江苏恒瑞医药股份有限公司 3r-氨基取代丁酰胺衍生物的制备方法
CN113880825A (zh) * 2020-07-01 2022-01-04 浙江海正药业股份有限公司 四氢异喹啉类衍生物的盐、其制备方法及其医药应用
CN114057751A (zh) * 2022-01-17 2022-02-18 盛世泰科生物医药技术(苏州)有限公司 一种dpp-iv抑制剂及其关键中间体的制备方法
CN115583935A (zh) * 2022-11-03 2023-01-10 浙江工业大学 一种4-(2,4,5-三氟苯基)-3-氧丁酸酯的制备方法

Also Published As

Publication number Publication date
US8518946B2 (en) 2013-08-27
CN102159578B (zh) 2013-04-10
KR101731602B1 (ko) 2017-04-28
RU2011137858A (ru) 2013-04-10
EP2404921A1 (en) 2012-01-11
AU2010220722A2 (en) 2011-11-03
AU2010220722A1 (en) 2011-10-27
CA2753862A1 (en) 2010-09-10
EP2404921A4 (en) 2012-08-15
US20120065209A1 (en) 2012-03-15
HK1154574A1 (en) 2012-04-27
ZA201107284B (en) 2012-12-27
WO2010099698A1 (zh) 2010-09-10
AU2010220722B2 (en) 2015-05-07
KR20110132561A (ko) 2011-12-08
UA106225C2 (ru) 2014-08-11
CN102159578A (zh) 2011-08-17
MX2011009190A (es) 2011-09-26
JP2012519193A (ja) 2012-08-23
EP2404921B1 (en) 2017-11-22
JP5976322B2 (ja) 2016-08-23
CA2753862C (en) 2017-05-23
RU2523543C2 (ru) 2014-07-20

Similar Documents

Publication Publication Date Title
CN102159578B (zh) 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
CA2673164C (en) Derivatives of azabicyclo octane, the method of making them and the uses thereof as inhibitors of dipeptidyl peptidase iv
TWI229081B (en) 2-phenyl-substituted imidazotriazinones
KR101704683B1 (ko) 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
CN101468988A (zh) 哌嗪类衍生物,其制备方法及其在医药上的应用
ES2273910T3 (es) Nuevos derivados de pirazolopiridinma substituidos con sulfonamida.
JP2012519193A5 (cg-RX-API-DMAC7.html)
BRPI0709764A2 (pt) derivados de biciclooctano, processo de preparaÇço e uso farmacÊutico do mesmo
BRPI0819719B1 (pt) Compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
JP2023549187A (ja) 貧血およびがんの処置のためのvhl阻害剤としての1-(2-(4-シクロプロピル-1h-1,2,3-トリアゾール-1-イル)アセチル)-4-ヒドロキシ-n-(ベンジル)ピロリジンe-2-カルボキサミド誘導体
CA2762917A1 (en) Salts of methyl (r)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylate
TW201412745A (zh) N-[2-({2-[(2S)-2-氰基吡咯啶-1-基]-2-側氧乙基}胺基)-2-甲基丙基]-2-甲基吡唑并[1,5-a]嘧啶-6-甲醯胺之結晶
CN103910734B (zh) 一种具有哌嗪结构的dpp-4抑制剂
JP2013526588A (ja) ヘキサヒドロピロロ[3,4−b]ピロール誘導体、その製造方法及び用途
WO2007054778A1 (en) Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as pde5 inhibitors
WO2023114366A2 (en) Sulfonamide derivatives and their use as soluble epoxide hydrolase inhibitors
DE10032874A1 (de) Arzneimittelkombinationen gegen virale Erkrankungen
CN104109147B (zh) 羟基脒基苯类衍生物及其制备方法和医药用途
CN114423775B (zh) 一类芳基葡糖苷衍生物及其制备方法和应用
KR20180020119A (ko) 새로운 5형포스포디에스테라아제 억제제 및 그 용도
CA3161134A1 (en) Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds
TWI522358B (zh) 四氫咪唑并〔1,5-a〕吡衍生物的鹽,其製備方法及其在醫藥上的應用
HK1154574B (en) Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100908